Preclinical studies by Bamodu et al. revealed that PDK1 drives radiotherapy resistance in HCC by activating the PI3K/AKT/mTOR signaling pathway, enhancing cancer stemness, and suppressing DNA damage, suggesting that targeting PDK1 could serve as a novel strategy to improve radiosensitivity [34]. This evidence concerns the gene MTOR and hepatocellular carcinoma.